产品
编 号：F622634
分子式：C22H16N6O2
分子量：396.4
分子式：C22H16N6O2
分子量：396.4
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1610610-48-4
产品详情
生物活性：
KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo. KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety.
体内研究：
KDU731 (orally administration; 7 or 10mg/kg; 16 days) has potent activity against Cryptosporidium in immunocompromised IFN-γ KO mice and dramatically reduces oocyst shedding.KDU731 (orally administration; 5 mg/kg; every 12 hours for 7 days) is tolerated in all calves, and treated calves shed significantly fewer oocysts than vehicle treated calves in their stool.Animal Model:6-8 week old C57BL/6 IFN-γ-knockout mice with 10,000 oocysts
Dosage:7 or 10 mg/kg
Administration:Orally administration; 7 or 10 mg/kg; 16 days
Result:Resulted in significant reduction of oocyst shedding.
Animal Model:Neonatal calves with 5 x 107 oocysts
Dosage:5 mg/kg
Administration:Orally administration; 5 mg/kg; every 12 hours for 7 days
Result:Resulted in significant reduction of oocyst shedding in treated calves in their stool.
KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo. KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety.
体内研究：
KDU731 (orally administration; 7 or 10mg/kg; 16 days) has potent activity against Cryptosporidium in immunocompromised IFN-γ KO mice and dramatically reduces oocyst shedding.KDU731 (orally administration; 5 mg/kg; every 12 hours for 7 days) is tolerated in all calves, and treated calves shed significantly fewer oocysts than vehicle treated calves in their stool.Animal Model:6-8 week old C57BL/6 IFN-γ-knockout mice with 10,000 oocysts
Dosage:7 or 10 mg/kg
Administration:Orally administration; 7 or 10 mg/kg; 16 days
Result:Resulted in significant reduction of oocyst shedding.
Animal Model:Neonatal calves with 5 x 107 oocysts
Dosage:5 mg/kg
Administration:Orally administration; 5 mg/kg; every 12 hours for 7 days
Result:Resulted in significant reduction of oocyst shedding in treated calves in their stool.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备